Slxn stock forecast on the valuation front

On the valuation front, SLXN stock forecast shows forward PEG ratio near 1.4, which is appealing compared to historical norms, possibly drawing value-focused funds back into the name. Stocks Telegraph www.stockstelegraph.com › quotes › SLXN Silexion's $6M offering provides short-term funding for pre-clinical RNAi cancer therapies but dilutes existing shareholders significantly. The latest SLXN stock forecast shows resilience in its recent price action, trading near $14.20 as of June 2024, with analysts projecting a potential upside toward the $16.00 level over the next quarter based on improved earnings guidance and favorable sector rotation into mid-cap tech.